ERBB2 and cancer: This antibody, specifically designed to deliver an antiproliferative agent to HER-2 overexpressing cancer cells, conjugates the targeted anti-HER-2 activity of trastuzumab with the intracellular cytotoxic effect of emtansine, a tubulin polymerase inhibitor [46].